This paper reviews the principles of the AAV vectors' generation. It describes various methods for their production and purification, as well as ways for increasing the efficiency and selectivity of the transduction by means of capsid modifications and use of various AAV serotypes. The second part of the article briefs clinical trials carried out so far with the use of the AAV vectors, particularly emphasizing the differences between feasibilities of vectors based on AAV and other virus types.
Jozef Dulak, Zaklad Biotechnologii Medycznej, Wydzial Biochemii, Biofizyki i Biotechnologii, Uniwersytet Jagiellonski, ul. Gronostajowa 7, 31-271 Krakow, Poland